Chris Gibson
Co-Founder & CEO
computational biologydrug discoveryAI/ML
Details
- ●Modalities: small molecules, precision chemistry
- ●Therapeutic areas: oncology, rare diseases, neuroscience
- ●Key targets: CDK4, AXIN1, RBM39, HDAC, superoxide scavengers
- ●Indications: cerebral cavernous malformation, neurofibromatosis type 2, familial adenomatous polyposis, C. difficile colitis
- ●Funding: $452M+ (pre-IPO)
Partners & investors
- SoftBank Vision Fund· Investor
- Baillie Gifford· Investor
- NVIDIA· Investor
- Lux Capital· Investor
Key considerations
- ●AI tools in use: Recursion OS (proprietary), LOWE (LLM), Phenom (phenomics), Exscientia Centaur Chemist
- ●Largest proprietary biological dataset in pharma (~2.6PB)
- ●NVIDIA BioNeMo partnership
- ●Acquired Exscientia for $688M (2024)
Pipeline
- Phase 11
- Phase 23
Get live updates on Recursion Pharmaceuticals’s hiring, filings, and partnerships. Follow in BT Pro →
Source: Company website, SEC / Companies House filings, press releases, Crunchbase · biotech.today analysis (Apr 2026)
Key people
Tina Larson
COO
biotech operationstechnology scaling